Immunotherapy for pulmonary TB: antimicrobial peptides and their inducers

Author: Rivas-Santiago Cesar Enrique   Hernández-Pando Rogelio   Rivas-Santiago Bruno  

Publisher: Future Medicine

ISSN: 1750-743X

Source: Immunotherapy, Vol.5, Iss.10, 2013-10, pp. : 1117-1126

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

TB is an infectious disease that still has an enormous impact on public health worldwide. With the continuous increasing epidemic of multidrug-resistant TB, new drugs and vaccines are urgently needed. In the last decade there has been a broad advance in the knowledge of innate immunity in TB. Together with the growing research regarding immunomodulators, new promising insights have been developed that can contribute in the control of TB. This is the case of antimicrobial peptides, which can be potential therapeutic or adjuvant agents. The current high cost of antimicrobial peptide synthesis may be a current deterrent for treatment; antimicrobial peptide-inducers can be an alternative for low-cost treatment and/or adjuvants.